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PURPOSE. Most of the uvea melanoma (UM) display a near-diploid (normal, ~2N) karyotype
with only a few chromosomal changes. In contrast to these simple aberrations 18% of the UM
samples show a polyploid character (>2N) and this was associated with an unfavorable
prognosis. This study attempts to gain insight in the prognostic value of polyploidy in UM.
METHODS. In 202 patients the ploidy status of the UM was determined using cytogenetic
analysis, fluorescence-in-situ-hybridization (FISH), multiplex ligation dependent probe
amplification (MLPA), and/or single nucleotide polymorphism (SNP) array analysis.
Immunohistochemistry was used to determine the BAP1 expression and mutation analyses
of BAP1 (coding regions) and the mutation hotspots for the SF3B1, EIF1AX, GNAQ, and
GNA11 genes was carried out using Sanger sequencing or whole-exome sequencing.
RESULTS. Twenty-three patients had a polyploid UM karyotype (11.4%). Patients with a
polyploid tumor had larger tumors (15.61 vs. 13.13 mm, P ¼ 0.004), and more often loss of
heterozygosity of chromosome 3 (P ¼ 0.003). No difference in occurrence of mutations
between polyploid and diploid tumors was observed for BAP1, SF3B1, EIF1AX, GNAQ, and
GNA11. Polyploidy did not affect survival (P ¼ 0.143). BAP1 deficiency was the only
significant independent prognostic predictor for patients with polyploid tumors, with a 16-
fold increased hazard ratio (HR 15.90, P ¼ 0.009).
CONCLUSIONS. The prevalence of mutations in the UM related genes is not different in polyploid
UM compared with diploid UM. Moreover, similar to patients with diploid UM, BAP1
mutation is the most significant prognostic predictor of metastasis in patients with polyploid
UM.
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Uveal melanoma (UM) is the most common primaryintraocular malignancy in adults with an annual incidence
of approximately 7 to 10 per million.1 In approximately one-half
of the patients UM metastasizes via the blood with a preference
for the liver.1 The prognostic factors linked to metastatic disease
include clinical variables (increased age, large tumor size),
histopathologic findings (epithelioid cell type, closed vascular
patterns), genetic, and chromosomal abnormalities (loss of
chromosome 3, gain of chromosome 8q).2–5
For UM, the karyotype is usually near-normal (diploid) with
only few nonrandom chromosomal changes, such as loss of
chromosome 3 (monosomy 3) and gain of chromosome 8q.6
Besides these near-diploid (~2N) tumors, UM with polyploidy
(>2N) have also been described. Based on DNA content, a
prevalence of 13% to 18% of polyploid UM has been observed.7–9
In addition to the prevalence, the prognostic value of the ploidy
was also described, in which polyploidy was associated with an
unfavorable prognosis.7,9 However, despite the impact on
survival, polyploidy in UM is not mentioned in recent literature
or investigated with the current knowledge of UM.
Nowadays in UM research, the focus is more on genetic
variations. Monosomy 3 in combination with the loss of
function of the tumor suppressor BAP1 (BRCA-associated
protein 1) is strongly associated with metastases.10–13 In
contrast, mutations in the SF3B1 (splicing factor 3 subunit
B1) gene and the EIF1AX (eukaryotic translation factor 1A)
gene are reported mainly in disomy 3 (no loss of chromosome
3) tumors.14–16 Therefore, mutations in SF3B1 or EIF1AX have
been suggested as favorable prognostic factors in UM, with low
risk of metastasis.10,14–17 Mutations in the oncogenes GNAQ
(Guanine nucleotide-binding protein, q polypeptide) and
GNA11 (Guanine nucleotide-binding protein, subunit alpha-
11) are present in the majority of UM and are not associated
with patient prognosis.18–20
This study attempts to describe the differences between
polyploid and diploid UM regarding clinical variables, histo-
pathologic findings, chromosomal abnormalities, and genetic
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mutations (BAP1, SF3B1, EIF1AX, GNAQ, and GNA11). We
also aimed to investigate the prognostic value of polyploidy
and prognostic factors within polyploid UM.
METHODS
Study Population
Tissue specimens were obtained from 324 patients with UM
who were enucleated or had a biopsy between 1993 and 2014.
Informed consent was given prior to enucleation and the study
was performed according to the guidelines of the Declaration
of Helsinki. This study was approved by the local ethics
committee. The clinical data from time of diagnosis until
December 2014 were updated from the patients’ chart. All
tumors were histopathologically confirmed. Tumor node
metastasis (TNM) classification of the UM was adapted from
the AJCC Cancer Staging Manual.21 Iris melanomas were
excluded from this study.
DNA Extraction and Copy Number Analysis
DNA was extracted directly from fresh tumor tissue or frozen
tumor using the QIAmp DNA-mini kit (Qiagen, Hilden,
Germany) according to the manufacturers’ instructions. Chro-
mosome abnormalities were described following the recom-
mendations for cytogenetic nomenclature.22 The tumors were
processed for fluorescence in situ hybridization (FISH), multi-
plex ligation dependent probe amplification (MLPA), and/or
single nucleotide polymorphism (SNP) array analysis (Illumina
HumanCytoSNP-12 v2.1 BeadChip and Illumina 610Q BeadChip;
Illumina, San Diego, CA, USA), as described previously.23 Cut-off
limits for deletion detected by FISH (>15% of the nuclei with
one signal) or amplification (>10% of the nuclei with 3 or more
signals) were adapted from the available literature.23
Tumor Ploidy
For this study, 202 of 324 patients were included for whom the
combination of several techniques was available to determine
the ploidy status of the tumor. A threshold of greater than 20%
polyploid cells was maintained for cytogenetic analyses. Based
on cytogenetic or SNP array analyses, selected chromosomes,
which were suspected to be 3N or 4N, were analyzed with
FISH to determine the ploidy fraction. A threshold of greater
than 10% of the nuclei with three or more signals of these
control chromosomes was used to classify a tumor as
polyploid.23 Based on literature, we assumed baseline ploidy
of polyploid UM as tetraploid (4N).24 Chromosomal copy
number changes were calculated based on the ploidy baseline.
For polyploid samples, chromosomes were treated as loss only
in combination with loss of heterozygosity (LOH). For
chromosome gain, both quantitative gain (>2N) as well as
relative gain (>4N) were included in the analyses of polyploid
UM.
Mutational Analyses
Mutation analyses using Sanger sequencing or obtained from
whole-exome sequencing (WES) was available for 126 samples.25
Variants found in the WES data were validated by Sanger
sequencing. BAP1, SF3B1, EIF1AX, GNAQ, and GNA11 mutation
analyses and BAP1 immunohistochemistry (IHC) were carried
out as reported previously.13,18,25,26 For five polyploid samples
no fresh or frozen tissue was available, therefore DNA was
isolated from formalin-fixed, paraffin-embedded (FFPE) tissue.
TABLE 1. Patient and Tumor Characteristics of the Study Cohort, and
Associations Between Ploidy of the Tumor With Other Clinical, Histopathologic,
and Genetic Variables
Variables, n ¼ 202
Ploidy Status Tumor
P Value
Polyploid,
Mean or n
Diploid,
Mean or n
Age at diagnoses 62.52 6 2.67 61.17 6 1.08 0.689†
Sex
Male 9 90 0.314‡
Female 14 89
Localization
Choroid 15 136 0.263‡
Ciliary body 8 43
Largest tumor diameter 15.61 6 0.76 13.13 6 0.25 0.004†
Tumor thickness 8.87 6 0.75 7.68 6 0.26 0.131†
TNM classification
Category 1 1 20 –
Category 2 5 66
Category 3 10 80
Category 4 7 13
Cell type
Spindle 4 59 0.129‡
Epithelioid/mixed 19 120
Extracellular matrix patterns
Absent 12 90 0.925‡
Present 11 86
Chromosome 3
Relative loss (<4N*) 23 98 <0.001‡
Normal (4N*) 0 81
Chromosome 3
LOH 20 98 0.003‡
No LOH 3 81
Chromosome 8q
Normal (2N) 0 69 <0.001‡
Absolute gain (>2N) 23 110
Chromosome 8q
Normal (4N*) 4 69 0.047‡
Gain (>4N*) 19 110
BAP1
Normal 8 69 0.223‡
Deficient 14 68
SF3B1
Wild-type 19 83 0.546‡
Mutated 4 25
EIF1AX
Wild-type 22 88 0.125§
Mutated 1 22
GNAQ
Wild-type 11 52 0.946‡
Mutated 12 55
GNA11
Wild-type 13 60 0.969‡
Mutated 10 47
P values  0.005 was considered significant after correction for multiple
testing. TNM classification was not compared since tumor diameter and thickness
are analyzed separately. Bold numbers indicate significant P values at P  0.005.
* Copy numbers for the polyploid UM.
† Mann-Whitney U test was used for associations with continuous data.
‡ v2 test or § Fisher’s exact test was used for associations with categorical data.
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These DNAs were screened for mutations in the UM genes using
the ION Torrent Personal Genome Machine (PGM) with the
supplier’s materials and protocols (Life Technologies, Carlsbad,
CA, USA). A custom primer panel was designed using the ION
AmpliSeq Designer 3.2 (Thermo Fisher Scientific, Waltham, MA,
USA). Reads were visualized with Integrative Genomics Viewer
(v2.3; Broad Institute, Cambridge, MA, USA). Variants were
validated with Sanger sequencing using primers (Supplementary
Table S1) and protocols for FFPE DNA. Protocols and designs
regarding FFPE DNA sequencing are available upon request. De
novo missense mutations were investigated with SIFT (in the
public domain, http://sift.jcvi.org/) and PolyPhen-2 (in the public
domain, http://genetics.bwh.harvard.edu/pph2/index.shtml) for
predictions on possible functional impact and pathogenicity of
the amino acid change.
Statistical Analyses
Disease-free survival (DFS) was calculated as date of first initial
treatment to date of clinically proven metastasis from UM. The
Log-rank test was used for categorical variables, and Cox
proportional hazard analysis for continuous variables. Statisti-
cal significant variables conducted from univariate analysis
were analyzed using Cox proportional hazard multivariate
analysis. P values of 0.05 or lower were considered significant
for survival analyses. v2 or Fisher’s exact test was used for
associations with categorical data; Mann-Whitney U test was
used for associations with continuous data. P values of 0.005 or
lower were considered significant for correlation analyses. All
statistical analyses were performed with SPSS 21.0 Software
(IBM, Armonk, NY, USA).
RESULTS
Patient and Tumor Characteristics
Polyploid UM was detected in 23 of 202 patients (11.4%). Nine
patients were male and 14 were female with a mean age at
diagnosis of 62.5 years. Mean tumor diameter was 15.6 mm
with a mean tumor thickness of 8.9 mm. Histopathologically,
19 tumors contained epithelioid cells and 11 formed extracel-
lular matrix patterns. All tumors (n¼23) showed a relative loss
of chromosome 3 (<4N), resulting in LOH for chromosome 3
in 20 tumors (Fig. 2), whereas three tumors (S28, S102, and
S156) still contained two different alleles despite the relative
loss (Figs. 1, 2). For chromosome 8q all polyploid UM had more
than two copies, 19 tumors had a relative gain (>4N), all
copies were present in three tumors (4N; S147, S156, and
S161) and one tumor (S75) had three copies of chromosome
8q (Fig. 1). An overview of the clinical, histopathologic, and
chromosomal variables are shown in Table 1.
Genetic Analyses UM Genes
Within the patients with polyploid tumors 12 patients
harbored a BAP1 mutation, which were hemi- or homozygous
in all cases. In 13 of 22 patients, the tumors did not express
BAP1 (examples provided in Fig. 3). In one case (S111) the lack
of tumor material restricted us to investigate BAP1 both for
mutations and expression. One patient (S76) could not be
investigated for BAP1 mutations, but did reveal loss of BAP1
expression. In one patient (S123), the tumor did not harbor a
mutation in the coding exons, but had a loss of expression of
BAP1 in the tumor. One patient (S121) harbored a missense
mutation in the tumor, p.E30G, whereas the IHC did show
expression of BAP1. This mutation was predicted as ‘Delete-
rious’ by SIFT software (J. Craig Venter Institute, Rockville, MD,
USA) and ‘Probably damaging’ by PolyPhen-2 software
(Harvard Medical School, Boston, MA, USA). All three patients
(S76, S121, and S123) were treated as BAP1-deficient tumors in
further analysis. SF3B1 was mutated in four samples targeting
the hotspot p.R625 in three cases and p.V576del in one case.
EIF1AX harbored a missense mutation, p.G15D, in one case,
which was predicted as ‘Deleterious’ by SIFT software and
‘Probably damaging’ by PolyPhen-2 software. Twelve tumors
harbored a GNAQ p.Q209 hotspot mutation, 10 harbored a
GNA11 p.Q209 hotspot mutation, and one tumor was wild-
type for exon 4 and 5 of both genes. An overview of the
mutations with the corresponding polyploid tumor is shown in
Figure 1.
Mutations in BAP1, SF3B1, EIF1AX, GNAQ, and GNA11 in
the patients with diploid UM were described previously.13,18,25
FIGURE 1. Overview of mutations and copy number variation in polyploid UM. The TNM classification is represented on the first line. First row of
blocks represent the GNAQ and GNA11 mutation status; dark gray, GNAQ mutation; light gray, GNA11 mutation; n.d. ¼ not determined; All
mutations were exclusive. Second row of blocks represent the BAP1, SF3B1, and EIF1AX mutation status; black, BAP1 mutation; striped, SF3B1
mutation; gray, EIF1AX mutation; and white, wild-type for the three genes. All mutations were exclusive. Third row of blocks represent the BAP1
expression; white, BAP1 expressed; black, BAP1 not expressed. Fifth row represent the alleles of chromosome 3; CNV ¼ copy number variation
(baseline is four copies); black, allele A; light gray, allele B; white, loss of chromosome. Sixth row represent the alleles of chromosome 8q; black,
allele A; light gray, allele B; white, loss of chromosome; dark gray, gain chromosome(s). * In these samples the BAP1 mutation status could not be
determined.
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Statistical Analyses
Based on tumor ploidy, patients did not differ in age at
diagnoses, sex, tumor localization, tumor thickness, cell type,
and presence of extracellular matrix patterns. Patients with a
polyploid tumor had significantly larger tumors than patients
with a diploid tumor (15.6 vs. 13.1 mm, P ¼ 0.004; Table 1).
For chromosomal abnormalities we classified the copy number
changes for polyploid UM in two ways. For chromosome loss,
we determined the relative loss from baseline and also loss
with LOH. For chromosome gain, we determined absolute gain
from disomy state and relative gain from baseline. Patients with
polyploid UM showed more loss of chromosome 3 (P < 0.001),
which was still significant after correcting for LOH (P¼ 0.003).
For chromosome 8q, the polyploid UM contained more often
absolute gain (>2N; P < 0.001). Relative gain of chromosome
8q was observed more often in polyploid UM (P¼ 0.047), and
after correcting the P value for multiple testing to P less than or
equal to 0.005 this was not considered significant. Mutational
frequencies did not differ between polyploid and diploid UM
for BAP1, SF3B1, EIF1AX, GNAQ, and GNA11.
Survival Analyses
To test whether polyploidy in UM was associated with worse
disease-free survival we performed survival analyses for the
total group (n ¼ 202). Ploidy was not associated with
prognosis, because patients with polyploid tumors, as a group,
did not differ from patients with diploid tumors based on the
survival (Fig. 4A). Univariate analyses results are shown in
Table 2. Also in the multivariate Cox-regression analyses,
polyploidy was not associated with disease-free survival. Larger
basal tumor diameter (HR 1.110; P ¼ 0.015) and BAP1
deficiency (HR 5.132; P < 0.001) were the only independent
significant predictors for disease-free survival in the total
cohort (Table 2).
Survival analysis was also performed for patients with
polyploid UM to investigate prognostic predictors within this
subset (n¼ 23). Loss of heterozygosity of chromosome 3 (P¼
0.050), BAP1 deficiency (P ¼ 0.001), and SF3B1 wild-type
mutation status (P ¼ 0.035) were significantly associated with
decreased disease-free survival. Other variables were not
significantly associated with disease-free survival (Table 2).
FIGURE 2. (A) Karyogram of S152 demonstrates a polyploid cell with three or four copies of most chromosomes and two copies of chromosome 3;
the corresponding whole-genome SNP array (all chromosomes on the X-axis) demonstrates a relative loss of chromosome 3 as observed in the Log R
ratio (negative values indicate a relative loss and positive values a relative gain). Loss of heterozygosity of chromosome 3 can be deduced from the B-
allele frequency (the B-allele frequency is either 1.0 or 0.0). (B) Karyogram of S28 demonstrates a polyploid cell with three or four copies of most
chromosomes and two copies of chromosome 3; the corresponding whole-genome SNP array demonstrates a relative loss as observed in the Log R
ratio; however, without the loss of heterozygosity as demonstrated by the SNP’s (B-allele frequency of ~0.5).
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Chromosome 3, BAP1, and SF3B1 status, together with tumor
diameter (because this was associated with polyploid UM)
were included into the multivariate Cox analyses. This showed
BAP1 deficiency as the only significant independent prognostic
predictor for patients with polyploid tumors, with a 16-fold
increased HR (HR 15.90, P ¼ 0.009; Table 2).
DISCUSSION
In our cohort polyploidy occurred in 11.4% of the patients
with UM. Previously, we as well as other groups have reported
ranges between 13% and 18%,8,9 and this difference in
prevalence can be explained by the different methods which
were used to determine the ploidy status and the DNA index
(DI) thresholds which were adapted to classify a tumor as
polyploid. Meecham et al.7 report polyploidy in 13% of the UM
with flow cytometry measurements and a threshold of DI
greater than 1.4 for polyploidy. Toti et al.9 report polyploidy in
18% of the UM cases, while maintaining a threshold of DI
greater than 1.3 for polyploidy, which would explain the
higher prevalence of polyploidy. Mooy et al.8 reports tetraploi-
dy (4N) in 17% of the cohort; however, this subset also
contains preirradiated tumors, which they also correlate to a
higher prevalence of aneuploidy.
When compared with patients with diploid UM, we found
larger tumor diameter in the polyploid patient group. Polyploid
UM also contained more LOH of chromosome 3. We could not
confirm previous findings, which stated that polyploidy as a
group is associated with worse patient survival.7,9 However,
we did find that BAP1 deficiency was the most significant
factor associated with survival in patients with a polyploid UM,
similar to diploid UM.
BAP1 expression has been shown as an independent
prognostic marker in UM.10,12,13 The gene is located on
chromosome 3, and is mutated mainly in tumors with loss of
chromosome 3,15 resulting in the loss of BAP1 expression.13
One sample harbored a missense mutation (p.E30G), whereas
the staining did reveal BAP1 expression. This mutation was
predicted ‘Deleterious’ and ‘Probably damaging’ by the
prediction software’s. Moreover, this mutation is located at
the first b-sheet of the protein and also next to three amino
acids (p.E31–p.Y33), which form a binding site for ubiquitin,27
making it likely that the replacement of the negatively charged
FIGURE 4. Kaplan-Meier survival analyses for; (A) polyploid UM compared to diploid UM (P¼ 0.143) and (B) survival analyses between polyploid
and diploid UM stratified for BAP1 status (P < 0.001).
FIGURE 3. Examples of BAP1 immunohistochemistry of two polyploid uveal melanoma cases. Left picture: BAP1 expression in the tumor cells of
S28 (3400). Right picture: lack of BAP1 expression in the tumor cells of the case S162 (3400). Note the positive staining in the retinal pigment
epithelium cells and macrophages.
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TABLE 2. Univariate and Multivariate Analyses of the Uveal Melanoma Parameters in Relation to Patient Survival for the Total Cohort and Patients
With a Polyploid Tumor Karyotype
Covariate
Univariate Multivariate
95% CI P Value HR 95% CI P Value
Total cohort, n ¼ 202
Age at diagnoses 1.006–1.036 0.004 0.683
Largest tumor diameter 1.030–1.158 0.003 1.110 1.021–1.206 0.015
Tumor height 0.997–1.113 0.065 – – –
Cell type
Spindle 121.7–160.9 <0.001 – – 0.912
Mixed/epithelioid 77.5–108.6
Closed vascular loops
Present 59.4–94.3 <0.001 – – 0.072
Absent 117.1–149.6
Ploidy
Diploid 99.6–128.0 0.143 – – 0.568
Polyploid 49.2–117.9
Chromosome 3
Loss, with LOH 50.6–80.1 <0.001 – – 0.549
Normal 147.1–175.7
Chromosome 8q
Normal 155.1–190.7 <0.001 2.171 0.958–4.920 0.063
Gain, relative 60.7–87.9
BAP1
Normal 141.2–172.5 <0.001 5.132 2.623–10.04 <0.001
Deficient 44.4–75.5
SF3B1
Wild-type 84.3–121.3 0.028 – – 0.166
Mutated 114.9–165.5
EIF1AX
Wild-type 75.9–106.8 <0.001 0.145 0.19–1.116 0.064
Mutated 168.3–214.6
Polyploid, n ¼ 23
Age at diagnoses 0.987–1.073 0.175 – – –
Largest tumor diameter 0.937–1.261 0.270 – – 0.156
Tumor height 0.909–1.229 0.471 – – –
Cell type
Spindle 22.0–149.2 0.624 – – –
Mixed/epithelioid
Closed vascular loops
Present 17.1–96.2 0.129 – – –
Absent 52.5–128.6
Ploidy
Diploid
Polyploid
Chromosome 3
Loss, with LOH * 0.050 – – 0.357
Normal
Chromosome 8q
Normal 66.5–167.4 0.136 – – –
Gain, relative 35.0–107.0
BAP1
Normal 123.7–211.5 0.001 15.90 1.97–128.3 0.009
Deficient 16.4–42.5
SF3B1
Wild-type * 0.035 – – 0.294
Mutated
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glutamic acid with the neutral glycine causes a structural
malformation of the protein resulting in a deficiency of BAP1.
The BAP1 expression can be explained, because the mutation
is a missense mutation and does not lead to protein
degradation. Also, the affected amino acid is located in the N-
terminal UCH domain, whereas the antibody used for the
staining target the C-terminal end of the BAP1 protein.13 In this
study, tumors with BAP1 mutations and/or loss of BAP1
expression were categorized as deficient BAP1. In this way we
observed that deficient BAP1 was the only independent
prognostic marker in patients with polyploid UM.
For the other UM relevant genes we found GNAQ or GNA11
mutations in all but one polyploid UM as one would expect
based on the occurrence described in diploid UM.19,20 SF3B1
mutations were observed in four of our polyploid tumors.
Patients with SF3B1 mutation in the UM have been associated
with the low-risk prognostic features; disomy 3, spindle-cell
type, and low age at diagnoses.15,16 None of the patients in our
polyploid group with SF3B1 mutations had developed meta-
static disease and were alive at the end of the study (follow-up
range, 1–192 months). Nevertheless, both to our own experi-
ence as well as by other groups patients can be identified with
disomy 3 tumors harboring an SF3B1 mutation that developed
metastasis.15,16,25,28 In our polyploid cohort the numbers are too
low and the follow-up for some tumors is too short in order to
draw conclusions regarding the influence of SF3B1 mutations in
the tumor on disease-free survival. EIF1AX mutations are mainly
reported in disomy 3 tumors and are correlated with a good
prognosis for these patients, and present in the tumor of one
patient in our series of polyploid UM, who is metastasis-free and
alive at a follow-up of 136 months.10,16,17,25 The missense
mutation found in the tumor of this patient affects amino acid 15
(p.G15D), a missense mutation described in other UM samples
as well (the COSMIC database; id¼COSM3973544; in the public
domain, http://cancer.sanger.ac.uk/cosmic/). The first 18 amino
acids at the N-terminus of the eiF1A protein are essential in the
interaction with the 40S subunit,29 thus making it very likely
that this mutation results in an altered function of the protein. In
this current study, we have shown that the prevalence of
mutations in the UM genes do not differ between tumors with
diploid and polyploid karyotypes, indicating a similar behavior
and progression toward metastatic disease, suggesting polyploid
UM are not a subclass in UM.
Caution should be taken in the interpretation of chromo-
somal abnormalities and using one technique only this could
possible lead to misclassifications. Uveal melanoma are
characterized by nonrandom recurring chromosomal losses
and gains.6 Loss of chromosome 3 has been correlated to
metastasis,3–5 but in polyploid UM with loss of one or multiple
copies of chromosome 3 this does not automatically result in
LOH. This is shown in our polyploid tumors, which all contain
a relative loss of chromosome 3, while three tumors do not
display a LOH (Figs. 1, 2). These three patients without LOH
are still alive with a median DFS of 11 years (range, 76–192
months), which is comparable to the survival of patients with
disomy 3 tumors.3 Onken et al.30 described that LOH of
chromosome 3 is superior to quantitative loss of monosomy 3,
and that is also the case in polyploid UM in our study. We
emphasize the importance of SNP-array to investigate the
zygosity of UM, to reduce false-negative (disomy 3 with LOH)
and false-positive (relative monosomy 3 without LOH) prog-
nostification. However, we cannot use the same reasoning for
chromosome gain. Increase in copies of chromosome 8q is
shown to be associated with shorter DFS.31 In polyploid UM,
all tumors contain more than two copies of 8q, while four
tumors do not have a relative gain based on the baseline of four
copies. One of these four patients developed liver metastasis at
54 months and is still alive after a partial hepatectomy 20
months later, two died due to another cause at 38 and 149
months respectively, and one is alive and metastasis-free at 76
months. Because the survival of these patients is not
homogenous we cannot draw conclusions regarding the
pathogenicity of absolute gain without relative gain (tri- and
tetrasomy) of chromosome 8q.
In conclusion, here we show that polyploid UM do not
differ from diploid UM based on prevalence of mutations in the
UM genes, and that similar to patients with diploid UM, BAP1 is
the most significant prognostic predictor of metastasis in
patients with polyploid UM (HR 15.90). Yet, the increased
chromosome count and frequent losses in polyploid tumors
can cause wrongful interpretations of chromosomal data and
should therefore be analyzed for ploidy status.
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